구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Erbitux | Toripalimab |
Overview Company | Eli Lilly / Merck KGaA | Junshi Biosciences |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Colorectal Cancer | Gastric Cancer |
Overview Indication | Head and Neck Cancer Squamous Cell | Metastatic Colorectal Cancer; Liver Metastases |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
Positioning Key differentiator | novel strategies of biotherapeutics | novel safety signals were identified |
Positioning Known limitation | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models | downregulation of p-Akt and Ki-67 |
MoA Mechanism | targeting the epidermal growth factor receptor | Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production |
MoA Biomarker | EGFR SR could be established with high | PD-L1)-positive |
PK/PD Half-life | 5.2 h | — |
PK/PD Species | Pig | Rat |
PK/PD Animal (cat.) | In vitro | Rat, In vitro |
PK/PD Experiment | Pharmacokinetic | PD |
Toxicology Species | Pig | Rat |
Toxicology Animal (cat.) | In vitro | Rat, In vitro |
Toxicology Major finding | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… | Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neo |
Clinical Safety signal | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… | Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neo |
Clinical Selected reported efficacy | ORR 52.2% | ORR 75.5% |
Clinical Reported ORR | 52.2% | 75.5% |
Clinical Reported PFS | — | 8.2 |
Clinical Reported OS | — | 33.7 |
Clinical Result source | ClinicalTrials.gov NCT00527111 | ClinicalTrials.gov NCT03581786 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT00527111 | NCT03581786 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Erbitux | Toripalimab |
Overview Company | Eli Lilly / Merck KGaA | Junshi Biosciences |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Colorectal Cancer | Gastric Cancer |
Overview Indication | Head and Neck Cancer Squamous Cell | Metastatic Colorectal Cancer; Liver Metastases |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
Positioning Key differentiator | novel strategies of biotherapeutics | novel safety signals were identified |
Positioning Known limitation | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models | downregulation of p-Akt and Ki-67 |
MoA Mechanism | targeting the epidermal growth factor receptor | Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production |
MoA Biomarker | EGFR SR could be established with high | PD-L1)-positive |
PK/PD Half-life | 5.2 h | — |
PK/PD Species | Pig | Rat |
PK/PD Animal (cat.) | In vitro | Rat, In vitro |
PK/PD Experiment | Pharmacokinetic | PD |
Toxicology Species | Pig | Rat |
Toxicology Animal (cat.) | In vitro | Rat, In vitro |
Toxicology Major finding | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… | Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neo |
Clinical Safety signal | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… | Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neo |
Clinical Selected reported efficacy | ORR 52.2% | ORR 75.5% |
Clinical Reported ORR | 52.2% | 75.5% |
Clinical Reported PFS | — | 8.2 |
Clinical Reported OS | — | 33.7 |
Clinical Result source | ClinicalTrials.gov NCT00527111 | ClinicalTrials.gov NCT03581786 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT00527111 | NCT03581786 |
추천 비교
추천 비교